Subcutaneous therapy improves inflammatory bowel disease treatment, clinical trial finds
Subcutaneous delivery of an anti-TNF inhibitor drug improved remission rates in patients with moderate-to-severe Crohn's disease and ulcerative colitis, according to recent phase 3 clinical trial results published in the ...
22 hours ago
0
8